Cytokine interference in infection
Cytokine interference in infection
Air date: Wednesday, June 12, 2019, 3:00:00 PM
Category: WALS - Wednesday Afternoon Lectures
Runtime: 00:58:35
Description: NIH Director's Wednesday Afternoon Lecture Series
Dr. O'Garra's laboratory studies cells and molecules that control our immune systems to understand how they respond to infections and influence the outcomes and what goes wrong when infections damage healthy cells. For example, some infected individuals are protected while others go on to progress to disease such as tuberculosis (TB), which is caused by infection with Mycobacterium tuberculosis (M. tuberculosis). TB is a major cause of morbidity and mortality worldwide and efforts to control this disease are hampered by difficulties with diagnosis, prevention, and treatment. Most people infected with M. tuberculosis remain asymptomatic or have latent (noninfectious) TB, but they have a 10 percent lifetime risk of developing the active form of the disease.
In 2010, Dr. O'Garra's laboratory identified a gene signature dominated by type I interferon (IFN) inducible genes in the bloodstream of people with TB, which disappears during successful treatment. The lab is also studying the regulation and function of type I IFNs which exacerbate bacterial infections, in part, by inducing a regulatory cytokine called IL-10.
Type I IFNs are cytokines that have been shown for years to be important in the control of viral infections. In experimental models, the lab showed that elevated levels of this cytokine lead to increased TB disease; subsequent studies now provide further knowledge regarding the heterogeneity of this blood signature in some, but not all, asymptomatic TB contacts and how this signature relates to whether they are protected or will develop the disease.
During the lecture, Dr. O'Garra will discuss several potential mechanisms underlying the contribution of type I IFN to the development of TB and diseases caused by other bacterial infections. She will also discuss the impairment of protective responses.
For more information go to https://oir.nih.gov/wals/2018-2019
Author: Anne O'Garra, Ph.D., Associate Research Director and Senior Group Leader, Laboratory of Immunoregulation and Infection, Francis Crick Institute
Permanent link: https://videocast.nih.gov/launch.asp?27613
Видео Cytokine interference in infection канала NIH VideoCast
Air date: Wednesday, June 12, 2019, 3:00:00 PM
Category: WALS - Wednesday Afternoon Lectures
Runtime: 00:58:35
Description: NIH Director's Wednesday Afternoon Lecture Series
Dr. O'Garra's laboratory studies cells and molecules that control our immune systems to understand how they respond to infections and influence the outcomes and what goes wrong when infections damage healthy cells. For example, some infected individuals are protected while others go on to progress to disease such as tuberculosis (TB), which is caused by infection with Mycobacterium tuberculosis (M. tuberculosis). TB is a major cause of morbidity and mortality worldwide and efforts to control this disease are hampered by difficulties with diagnosis, prevention, and treatment. Most people infected with M. tuberculosis remain asymptomatic or have latent (noninfectious) TB, but they have a 10 percent lifetime risk of developing the active form of the disease.
In 2010, Dr. O'Garra's laboratory identified a gene signature dominated by type I interferon (IFN) inducible genes in the bloodstream of people with TB, which disappears during successful treatment. The lab is also studying the regulation and function of type I IFNs which exacerbate bacterial infections, in part, by inducing a regulatory cytokine called IL-10.
Type I IFNs are cytokines that have been shown for years to be important in the control of viral infections. In experimental models, the lab showed that elevated levels of this cytokine lead to increased TB disease; subsequent studies now provide further knowledge regarding the heterogeneity of this blood signature in some, but not all, asymptomatic TB contacts and how this signature relates to whether they are protected or will develop the disease.
During the lecture, Dr. O'Garra will discuss several potential mechanisms underlying the contribution of type I IFN to the development of TB and diseases caused by other bacterial infections. She will also discuss the impairment of protective responses.
For more information go to https://oir.nih.gov/wals/2018-2019
Author: Anne O'Garra, Ph.D., Associate Research Director and Senior Group Leader, Laboratory of Immunoregulation and Infection, Francis Crick Institute
Permanent link: https://videocast.nih.gov/launch.asp?27613
Видео Cytokine interference in infection канала NIH VideoCast
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Gaining New Insights into 'Fundamental Immunology' Using Imaging and Computation](https://i.ytimg.com/vi/pWT98jkY0a4/default.jpg)
![Heterogeneity of Breast Cancer Genomes](https://i.ytimg.com/vi/mh4NH4q9QU0/default.jpg)
![Quality Management in Clinical Research: Preparing for a Successful Quality Visit Part 2](https://i.ytimg.com/vi/3SVjq_tzxNQ/default.jpg)
![Data and Safety Monitoring Committees: Trials Needing DSMBs Part 4](https://i.ytimg.com/vi/oWK_q84I_6Y/default.jpg)
![2018 Demystifying Medicine: Compulsive disorders: mechanisms and management](https://i.ytimg.com/vi/66AYPnccN2Q/default.jpg)
![Antibodies Against Ebola and Lassa: A Global Collaboration](https://i.ytimg.com/vi/Zzy-BCMCed8/default.jpg)
![Neuronal Response to Injury and Stress: Insights from C. elegans](https://i.ytimg.com/vi/T_wKKzIX_N0/default.jpg)
![Study Participant Selection: Example of Participant Selection Part 3](https://i.ytimg.com/vi/uO6MF_9YQG0/default.jpg)
![Choosing a Research Question: Developing a Hypothesis and Objectives Part 3](https://i.ytimg.com/vi/eeRV-t0smt8/default.jpg)
![In Vitro Approaches to Investigate Cell Division and Biological Size Control](https://i.ytimg.com/vi/MqckH7AIoN8/default.jpg)
![Data Management & Case Report in Clinical Trials: CRF Completion and Query Resolution Part 3](https://i.ytimg.com/vi/khl72phrKFY/default.jpg)
![WALS "Quantitative Proteomics for Understanding Epigenetics Mechanisms"](https://i.ytimg.com/vi/_aMR9RM25HE/default.jpg)
![Quality of Life: Patient Reported Outcomes: Purpose, Types, Development, and Evaluation Part 1](https://i.ytimg.com/vi/4mcaUOMBDRo/default.jpg)
![Medal Winners: How the Vietnam War Launched Nobel Careers](https://i.ytimg.com/vi/cSRDwF5kuLI/default.jpg)
![Quality of Life: Interpretation of PRO Scores Part 3](https://i.ytimg.com/vi/KlK-ky_NSJw/default.jpg)
![Developing Protocols & Manuals of Operating Procedures: Informed Consent & Conclusions Part 5](https://i.ytimg.com/vi/evLzCOF39lk/default.jpg)
![Introduction to Clinical Study Design: Tips for Good Study Design Part 4](https://i.ytimg.com/vi/rWAF8tbc_kA/default.jpg)
![Designing Trials Efficiently: Review of Sample Size Considerations Part 2.](https://i.ytimg.com/vi/YzgRxYKenC8/default.jpg)
![Research With Vulnerable Participants: Vulnerabilities and Safeguards Part 2](https://i.ytimg.com/vi/b-2EL8nFlEw/default.jpg)
![Demystifying Medicine 2015 - New Advances in Cancer Diagnosis and Treatment (Immunotoxins)](https://i.ytimg.com/vi/kqDY8J_HMEU/default.jpg)
![IPPCR 2019 Overview of Hypothesis Testing Part 4 of 5](https://i.ytimg.com/vi/nMo6vbZnGu4/default.jpg)